🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

⁦Dr Roy Chemaly⁩ !!!! linkedin.com/posts/msd-bras…

Great evening discussing “Infectious diseases in CAR-T cell therapy recipients” with Joseph Sassine!!! Jayr Schmidt Filho Thank you for sharing your experience with us! #TxID #cartcelltherapy #ACCamargoCancerCenter #EspecializadoemVida #Next2023 #NextFrontierstoCureCancer

Cytomegalovirus Viral Load Threshold to Guide Preemptive Therapy in Hematopoietic Cell Transplant Recipients: Correlation with CMV Disease ✅ Just Accepted 🔗 bit.ly/460e5Ds

So glad to hear Dr. Harrys Torres talking about HBV reactivation in cancer patients, in our ID course at BI BOB !!! We learned a lot with you 🙏 #accamargo #MDACC

.ASTCT Transplantation and Cellular Therapy Journal ASH Clinical News ASH UVA Department of Medicine UVA Cancer Center

A medicine that prevents serious side effects after #BMT may increase the risk of infections, according to a new CIBMTR study. Read more about the study, here: cibmtr.org/Files/Patient-…

Amazing section about “What´s New in CMV Management in HSCT?Latest Clinical Advances “ with great speakers Dr Roy Chemaly Dr. Per Ljungman, Dr. Rafael de La Camara and Dr. Jan Styczynski at #EBMT24 The EBMT #CMVisNotMyFriend

A total cost of care was compared for letermovir prophylaxis versus preemptive therapy. For high-risk pts, letermovir decreases total cost of care through day+180 and for standard-risk pts, letermovir reduces inpatient cost of care through day+180. astctjournal.org/article/S2666-…

#ICHSglobal now had country ambassadors to disseminate information about #immunocompromised host information throughout the world. Welcome them!

#NIAID researchers & partners developed a method to detect #tuberculosis (TB) in animal lungs using a PET scan & novel tracer specific for TB. Clinical studies are needed to confirm if the method is safe & accurate at identifying TB in people. Learn more: nature.com/articles/s4146…

🌟✨ É com grande alegria que anuncio minha nomeação como Embaixadora Nacional da International Immunocompromised Host Society (ICHS) International Immunocompromised Host Society no Brasil! 🎉 lnkd.in/dwDD-MCG Como Embaixadora, terei a responsabilidade de: •Promover a

Out now in TransplantID Journal! T-SPOT.TB is more likely to produce actionable results than QFT-TB in patients with cancer being screened for latent TB. With Marjorie V Batista MD, TID, PhD Dr Roy Chemaly Prathit Kulkarni, MD Firas El Chaer, MD, MSHCM Georgios Angelidakis MD Anderson Cancer Center #TxID onlinelibrary.wiley.com/doi/10.1111/ti…

You see a young person with this appearance. What’s the diagnosis?

ICHS Educational Resources There is a new educational resource to view at your convenience! The recording of the recent CMV webinar is now available. This is free for members and for most levels. Click here to register and receive the recording: buff.ly/41QkLVx

ICHS New Resources With efforts from the ICHS Ambassadors, new regional and country resources have recently been added to the ICHS website. For more information on these resources, please visit the ICHS Related Societies page here: buff.ly/40tglme

Connect with the Experts at this dynamic webinar: Take advantage of this opportunity and submit your questions to the experts for the “Controversies in the Vaccination of Immunocompromised Patients,” webinar on February 6, 2025. Please visit: buff.ly/4a8g77q

New Resources Now Available: Thanks to the dedicated efforts of the ICHS Ambassadors, new regional and country-specific resources have been added to the ICHS website. To explore these newly available resources, visit the ICHS Related Societies page here: buff.ly/40tglme.

Excellent session today at the International Project ECHO Clinic on Viral Hepatitis MD Anderson Cancer Center. Drs. Viera and Gibran from A.C. Camargo Cancer Center, São Paulo, Brazil discussed #HepB in patients with CAR-T. #HepatitisElimination #endcancer

ONE WEEK LEFT TO REGISTER: Dengue en inmunocomprometidos: lo que aprendimos y lo que falta saber. Dengue in immunocompromised host: lessons learned and knowledge gaps. Register Here - Today: ichs.org/page-1863370